OraSure Technologies Revenue and Competitors

Bethlehem, PA USA

Location

N/A

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • OraSure Technologies's estimated annual revenue is currently $232.9M per year.(i)
  • OraSure Technologies's estimated revenue per employee is $418,867
  • OraSure Technologies's current valuation is $613M. (January 2022)

Employee Data

  • OraSure Technologies has 556 Employees.(i)
  • OraSure Technologies grew their employee count by -5% last year.

OraSure Technologies's People

NameTitleEmail/Phone
1
Snr. VP Finance & ControllerReveal Email/Phone
2
Chief Financial OfficerReveal Email/Phone
3
SVP Finance & Chief Accounting OfficerReveal Email/Phone
4
VP Financial Planning, Analysis & Sales OperationsReveal Email/Phone
5
SVP, Global OperationsReveal Email/Phone
6
EVPReveal Email/Phone
7
EVP, Business Unit Leader, Molecular SolutionsReveal Email/Phone
8
Head Research and New DiagnosticsReveal Email/Phone
9
VP Medical and Governmental AffairsReveal Email/Phone
10
VP, US Sales, Diagnostics Business UnitReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$1.6M100%N/AN/A
#2
$4M2613%N/AN/A
#3
$0.9M6-14%N/AN/A
#4
$1.1M70%N/AN/A
#5
$10.9M703%N/AN/A
#6
$0.7M929%N/AN/A
#7
$4M26-16%N/AN/A
#8
$1.7M1122%N/AN/A
#9
$7.6M492%N/AN/A
#10
$1.6M100%N/AN/A
Add Company

What Is OraSure Technologies?

Based in Bethlehem, Pennsylvania, OraSure Technologies is a leader in the development, manufacture and distribution of oral fluid diagnostic and collection devices and other technologies designed to detect or diagnose critical medical conditions. These products include tests for the detection of antibodies to the HIV virus, including the OraQuick® In-Home HIV Test, OraQuick ADVANCE® Rapid HIV-1/2 Antibody Test and the OraSure® HIV-1 Oral Specimen Collection Device, a test for antibodies to the HCV virus, the OraQuick® HCV Rapid Antibody Test, and oral fluid testing solutions for drugs of abuse testing, including Intercept® Oral Fluid Drug Testing System and Q.E.D.® Saliva Alcohol Test. OraSure also manufactures and sells several leading cryosurgical products. These include: Histofreezer®, a product for the cryosurgical removal of common and plantar warts and several other benign skin lesions, sold to the professional or physician office market, as well as an over-the-counter product for the cryosurgical removal of common and plantar warts. In addition, through its wholly-owned subsidiary, DNA Genotek Inc., the Company also is a leading provider of oral fluid sample collection, stabilization and preparation products for molecular diagnostic applications. OraSure's portfolio of products is sold globally to various clinical laboratories, hospitals, clinics, community-based organizations and other public health organizations, research and academic institutions, distributors, government agencies, physicians' offices, and commercial and industrial entities. Its over the counter products are available in pharmacies across North America, South America, Europe, and Australia.

keywords:Biotechnology,Healthcare,Medical Devices,Medical Diagnostics,Pharmaceuticals

N/A

Total Funding

556

Number of Employees

$232.9M

Revenue (est)

-5%

Employee Growth %

$613M

Valuation

N/A

Accelerator

OraSure Technologies News

2022-04-17 - OraSure Technologies (NASDAQ:OSUR) Downgraded by StockNews.com to "Sell" MarketBeat

OraSure Technologies (NASDAQ:OSUR) Downgraded by StockNews.com to "Sell" MarketBeat

2022-04-06 - OraSure Technologies' Subsidiary DNA Genotek Launches the First ... GlobeNewswire

OraSure Technologies' Subsidiary DNA Genotek Launches the First ... GlobeNewswire

2022-03-30 - OraSure Technologies' Subsidiary Diversigen Launches ... GlobeNewswire

OraSure Technologies' Subsidiary Diversigen Launches ... GlobeNewswire

2021-11-03 - OraSure Technologies Reports 3Q21 Revenue of $53.9 Million, Signs Three Major U.S. Government Contracts Positioning the Company for Significant InteliSwab™ Growth in FY22

Third quarter revenue of $53.9 million grew 12% year-over-year; excluding COVID-19 product revenues, revenues for the quarter grew 37% from the prior year, demonstrating strong growth OraSure signs three major U.S. government contracts providing $205 million in government InteliSwab™ procurement ...

2021-11-02 - U.S. FDA Authorizes InteliSwab™ COVID-19 Rapid Tests for OTC Single-Use, At-Home Testing for Symptomatic People and Accepts Data for Delta Variant Detection

BETHLEHEM, Pa., Nov. 02, 2021 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a global leader in point-of-care and home diagnostic testing and sample collection technologies, announced today that the EUA for its InteliSwab™ COVID-19 rapid tests has been amended by the U.S. Food an ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$71M568N/AN/A
#2
$750M638-3%N/A
#3
$109.9M70924%N/A
#4
$370.7M9135%N/A
#5
$300M3582N/AN/A

OraSure Technologies Funding

DateAmountRoundLead InvestorsReference
2002-09-17$10.9MCredit FacilityComericaArticle
2019-01-07$3687890Article